Clinical experience with fondaparinux in antiaggregate patients undergoing total hip and knee arthroplasty

Submitted: 26 July 2013
Accepted: 26 July 2013
Published: 19 September 2013
Abstract Views: 1261
PDF: 935
HTML: 324
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Patients undergoing total hip arthroplasty or total knee arthroplasty have a high risk for post-operative venous thromboembolism. The current study addressed the use of fondaparinux post-operatively in 556 patients with antiplatelet therapy in order to prevent deep vein thrombosis as well as demonstrate efficacy in preventing arterial thrombotic events. Results provided evidence for a safe and effective prophylaxis strategy, involving the change from low molecular weight heparin pre-operatively to fondaparinux postoperatively. Also, fondaparinux proved effective as a unique post-operative therapy in the prevention of venous thromboembolism with no adverse effects, such as major bleeding or arterial thrombosis in patients with pre-operative antiplatelet therapy.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

How to Cite

Grappiolo, G., Scardino, M., Mazziotta, G., Quaini, S., Lodigiani, C., & Ferrari, M. C. (2013). Clinical experience with fondaparinux in antiaggregate patients undergoing total hip and knee arthroplasty. Italian Journal of Medicine, 7(3), 179–182. https://doi.org/10.4081/itjm.2013.179